Resulting from over ten years of research in microfluidic and stem-cell engineering, HemostOD has developed a unique bioreactor that enables the manufacturing of ex-vivo platelets in just a few hours. The startup’s technology provides a revolutionary alternative to today’s blood donor platelets system with reliable access and long-run cost-effectiveness. The immune neutrality of platelets thereby produced represent a major breakthrough for allo-immunized patients and cancel out alloimmunization for at-risk patients. With their solution, HemostOD creates a new source of platelets, manufactured on-demand, to relieve blood banks and hospitals.
The startup has secured fresh capital in a seed financing round led by Orenok Holdings SA.. The proceeds will support progression towards clinical stages, which will also lead to the scale-up of the technology, the development of an unlimited source of platelet mother cells and the consolidation of the manufacturing process and pre-clinical package in accordance with regulatory authorities.
HemostOD appoints president of its board of directors
In line with the financing round, HemostOD has welcome Laurent Massuyeau, President of Orenok Holdings and CEO of iQone Healthcare, as President of HemostOD’s board of directors. With 30 years of experience in the pharmaceutical industry, his contribution will be key for developing HemostOD’s product, future market launch and overall success. Faouzi Khechana, the co-founder of HemostOD, remains CEO and will continue to lead operations and strategic developments.
“The technology platform developed by HemostOD is very promising and is opening the door to providing solutions to longstanding medical needs. This financing round is an important step towards achieving the next company milestones as planned by the HemostOD team,” commented Massuyeau.
(Press release/RAN)
Please login or sign up to comment.
Commenting guidelines